Kathleen Marie Powis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 41 | 2024 | 2149 | 5.620 |
Why?
|
| HIV Infections | 81 | 2024 | 17342 | 3.880 |
Why?
|
| Infectious Disease Transmission, Vertical | 27 | 2024 | 1351 | 2.770 |
Why?
|
| Botswana | 43 | 2024 | 1049 | 2.310 |
Why?
|
| Anti-HIV Agents | 25 | 2024 | 4524 | 2.290 |
Why?
|
| Anti-Retroviral Agents | 18 | 2024 | 1783 | 1.500 |
Why?
|
| HIV-1 | 21 | 2024 | 6858 | 1.290 |
Why?
|
| Zidovudine | 9 | 2024 | 624 | 1.180 |
Why?
|
| Pregnancy | 56 | 2024 | 29869 | 1.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 15 | 2020 | 1894 | 1.010 |
Why?
|
| HIV Protease Inhibitors | 4 | 2022 | 432 | 0.750 |
Why?
|
| Infant Mortality | 5 | 2019 | 751 | 0.740 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 224 | 0.720 |
Why?
|
| Infant | 34 | 2024 | 36157 | 0.700 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2024 | 339 | 0.640 |
Why?
|
| HIV | 9 | 2023 | 1580 | 0.640 |
Why?
|
| Premature Birth | 8 | 2023 | 1782 | 0.610 |
Why?
|
| Circumcision, Male | 5 | 2020 | 148 | 0.600 |
Why?
|
| Viral Load | 12 | 2023 | 3325 | 0.560 |
Why?
|
| Body Height | 2 | 2021 | 1565 | 0.560 |
Why?
|
| RNA, Viral | 7 | 2018 | 2838 | 0.550 |
Why?
|
| Fetus | 2 | 2021 | 1862 | 0.550 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2023 | 2197 | 0.530 |
Why?
|
| Infant, Newborn | 28 | 2024 | 26183 | 0.520 |
Why?
|
| Nevirapine | 6 | 2024 | 273 | 0.500 |
Why?
|
| Breast Feeding | 8 | 2023 | 1355 | 0.500 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2024 | 2518 | 0.470 |
Why?
|
| Birth Weight | 3 | 2023 | 2101 | 0.460 |
Why?
|
| Mothers | 5 | 2024 | 2194 | 0.440 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 461 | 0.440 |
Why?
|
| Oxazines | 4 | 2024 | 349 | 0.420 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2022 | 621 | 0.420 |
Why?
|
| Malnutrition | 1 | 2019 | 622 | 0.420 |
Why?
|
| Female | 77 | 2024 | 392203 | 0.410 |
Why?
|
| Insulin Resistance | 2 | 2024 | 3954 | 0.400 |
Why?
|
| Benzoxazines | 4 | 2024 | 316 | 0.400 |
Why?
|
| Maternal Exposure | 1 | 2019 | 1067 | 0.390 |
Why?
|
| Child | 24 | 2024 | 80089 | 0.370 |
Why?
|
| South Africa | 3 | 2022 | 1843 | 0.370 |
Why?
|
| Communicable Diseases | 1 | 2019 | 871 | 0.360 |
Why?
|
| Tuberculosis | 1 | 2023 | 2015 | 0.360 |
Why?
|
| Child Development | 4 | 2019 | 2300 | 0.360 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2022 | 287 | 0.350 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 580 | 0.350 |
Why?
|
| HIV Seropositivity | 3 | 2022 | 959 | 0.350 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 1049 | 0.350 |
Why?
|
| Progesterone | 1 | 2014 | 742 | 0.340 |
Why?
|
| Developmental Disabilities | 2 | 2016 | 1509 | 0.340 |
Why?
|
| Pyridones | 4 | 2024 | 808 | 0.330 |
Why?
|
| Humans | 93 | 2024 | 760740 | 0.330 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 1230 | 0.330 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2218 | 0.330 |
Why?
|
| Population Surveillance | 1 | 2019 | 2597 | 0.320 |
Why?
|
| Fetal Development | 1 | 2014 | 769 | 0.310 |
Why?
|
| Alkynes | 4 | 2024 | 320 | 0.300 |
Why?
|
| Cyclopropanes | 4 | 2024 | 432 | 0.290 |
Why?
|
| Anthropometry | 3 | 2021 | 1338 | 0.290 |
Why?
|
| Pneumonia | 1 | 2019 | 2143 | 0.290 |
Why?
|
| Stillbirth | 5 | 2023 | 368 | 0.290 |
Why?
|
| Postpartum Period | 4 | 2022 | 1178 | 0.260 |
Why?
|
| Pregnancy Outcome | 5 | 2024 | 2921 | 0.260 |
Why?
|
| Protease Inhibitors | 3 | 2022 | 753 | 0.250 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 1388 | 0.240 |
Why?
|
| Prevalence | 11 | 2024 | 15702 | 0.230 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2024 | 38 | 0.220 |
Why?
|
| Adenosine Monophosphate | 1 | 2024 | 231 | 0.210 |
Why?
|
| Trichomonas Infections | 1 | 2022 | 41 | 0.210 |
Why?
|
| Piperazines | 3 | 2022 | 2521 | 0.210 |
Why?
|
| Trichomonas vaginalis | 1 | 2022 | 70 | 0.200 |
Why?
|
| Lamivudine | 2 | 2024 | 366 | 0.200 |
Why?
|
| Alanine | 1 | 2024 | 609 | 0.190 |
Why?
|
| Adult | 37 | 2024 | 220995 | 0.190 |
Why?
|
| Zambia | 1 | 2022 | 272 | 0.190 |
Why?
|
| Ritonavir | 2 | 2022 | 329 | 0.180 |
Why?
|
| Prospective Studies | 15 | 2024 | 54364 | 0.180 |
Why?
|
| Zimbabwe | 1 | 2021 | 135 | 0.180 |
Why?
|
| Vitamin D | 1 | 2014 | 3301 | 0.180 |
Why?
|
| Integrase Inhibitors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
| Syphilis | 1 | 2022 | 243 | 0.170 |
Why?
|
| Young Adult | 22 | 2024 | 59191 | 0.170 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 908 | 0.170 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 155 | 0.170 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 130 | 0.170 |
Why?
|
| Infant Formula | 1 | 2021 | 194 | 0.170 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 121 | 0.170 |
Why?
|
| Hepatitis B Vaccines | 1 | 2020 | 177 | 0.160 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 365 | 0.160 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 294 | 0.160 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 328 | 0.160 |
Why?
|
| Parturition | 3 | 2023 | 447 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7403 | 0.160 |
Why?
|
| Paternal Exposure | 1 | 2019 | 96 | 0.160 |
Why?
|
| Rural Population | 5 | 2021 | 2277 | 0.160 |
Why?
|
| Quarantine | 1 | 2020 | 182 | 0.150 |
Why?
|
| Gonorrhea | 1 | 2022 | 346 | 0.150 |
Why?
|
| Pregnancy Complications | 2 | 2023 | 2948 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 258 | 0.150 |
Why?
|
| Hospitalization | 6 | 2021 | 10708 | 0.150 |
Why?
|
| Integrases | 1 | 2020 | 518 | 0.140 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 517 | 0.140 |
Why?
|
| Adolescent | 16 | 2024 | 88247 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 397 | 0.140 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 527 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2018 | 2567 | 0.140 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 661 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 767 | 0.140 |
Why?
|
| Male | 31 | 2024 | 360402 | 0.140 |
Why?
|
| Africa South of the Sahara | 1 | 2019 | 745 | 0.130 |
Why?
|
| Serologic Tests | 1 | 2018 | 381 | 0.130 |
Why?
|
| HIV Antibodies | 4 | 2024 | 1302 | 0.120 |
Why?
|
| Energy Metabolism | 2 | 2017 | 2878 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2024 | 3037 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2020 | 704 | 0.120 |
Why?
|
| Child Mortality | 1 | 2016 | 199 | 0.110 |
Why?
|
| Child, Preschool | 9 | 2024 | 42193 | 0.110 |
Why?
|
| Hypertension | 4 | 2023 | 8532 | 0.110 |
Why?
|
| Diarrhea | 1 | 2020 | 1317 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2024 | 41464 | 0.110 |
Why?
|
| Prilocaine | 1 | 2012 | 21 | 0.110 |
Why?
|
| Foreskin | 1 | 2012 | 33 | 0.100 |
Why?
|
| Anemia | 2 | 2013 | 1504 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2021 | 6223 | 0.100 |
Why?
|
| Neonatal Screening | 1 | 2017 | 597 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 637 | 0.100 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 865 | 0.100 |
Why?
|
| United States | 9 | 2024 | 72292 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2013 | 222 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2021 | 22153 | 0.100 |
Why?
|
| Placental Insufficiency | 1 | 2012 | 50 | 0.100 |
Why?
|
| Vaccination | 1 | 2024 | 3370 | 0.100 |
Why?
|
| Equipment and Supplies | 1 | 2014 | 273 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 1250 | 0.090 |
Why?
|
| Immunity, Innate | 2 | 2022 | 3045 | 0.090 |
Why?
|
| Linear Models | 1 | 2021 | 5866 | 0.090 |
Why?
|
| Feces | 1 | 2017 | 1490 | 0.090 |
Why?
|
| Neutropenia | 2 | 2013 | 885 | 0.090 |
Why?
|
| Proviruses | 2 | 2023 | 313 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.080 |
Why?
|
| Lidocaine | 1 | 2012 | 538 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2019 | 2092 | 0.080 |
Why?
|
| Mass Screening | 3 | 2020 | 5425 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 4028 | 0.080 |
Why?
|
| Seasons | 1 | 2014 | 1518 | 0.080 |
Why?
|
| Edema | 1 | 2012 | 765 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2013 | 861 | 0.080 |
Why?
|
| Body Size | 1 | 2011 | 463 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2019 | 23974 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4010 | 0.070 |
Why?
|
| Cameroon | 2 | 2017 | 76 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 846 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 10203 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 983 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 3805 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2017 | 4210 | 0.060 |
Why?
|
| Body Weight | 1 | 2016 | 4615 | 0.060 |
Why?
|
| Mitochondria | 1 | 2017 | 3619 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5886 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2570 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2020 | 462 | 0.060 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2017 | 269 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 1936 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 26065 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3351 | 0.060 |
Why?
|
| Risk Factors | 9 | 2023 | 74128 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2017 | 12333 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2023 | 4365 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7390 | 0.050 |
Why?
|
| Fertilization | 1 | 2023 | 198 | 0.050 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 2191 | 0.050 |
Why?
|
| Weight Gain | 2 | 2022 | 2349 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2023 | 347 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 239 | 0.050 |
Why?
|
| Sex Factors | 1 | 2014 | 10549 | 0.040 |
Why?
|
| Insulin | 1 | 2015 | 6593 | 0.040 |
Why?
|
| Viremia | 1 | 2023 | 706 | 0.040 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2022 | 239 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2013 | 5292 | 0.040 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 709 | 0.040 |
Why?
|
| Quinolones | 1 | 2022 | 378 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2017 | 80583 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 165 | 0.040 |
Why?
|
| Placenta | 2 | 2022 | 1709 | 0.040 |
Why?
|
| Logistic Models | 1 | 2013 | 13248 | 0.040 |
Why?
|
| Incidence | 4 | 2019 | 21339 | 0.040 |
Why?
|
| HIV Antigens | 1 | 2018 | 325 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 12448 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 441 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 561 | 0.040 |
Why?
|
| Parity | 1 | 2020 | 924 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 714 | 0.030 |
Why?
|
| Carnitine | 1 | 2017 | 252 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1834 | 0.030 |
Why?
|
| Morbidity | 1 | 2021 | 1750 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 14599 | 0.030 |
Why?
|
| Middle Aged | 9 | 2020 | 220603 | 0.030 |
Why?
|
| Hospitals, District | 1 | 2016 | 114 | 0.030 |
Why?
|
| Cannabis | 1 | 2021 | 441 | 0.030 |
Why?
|
| United Nations | 1 | 2016 | 149 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 786 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 846 | 0.030 |
Why?
|
| Counseling | 1 | 2022 | 1538 | 0.030 |
Why?
|
| Awareness | 1 | 2018 | 649 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2023 | 3205 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2018 | 800 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2024 | 1521 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2020 | 1754 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 10072 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 2805 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2016 | 701 | 0.020 |
Why?
|
| Caregivers | 1 | 2024 | 2241 | 0.020 |
Why?
|
| Overweight | 1 | 2022 | 2417 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 1186 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 1067 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3820 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2016 | 992 | 0.020 |
Why?
|
| Community Health Services | 1 | 2016 | 654 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2018 | 2703 | 0.020 |
Why?
|
| Goals | 1 | 2016 | 708 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2012 | 703 | 0.020 |
Why?
|
| Monocytes | 1 | 2019 | 2565 | 0.020 |
Why?
|
| Gestational Age | 1 | 2019 | 3577 | 0.020 |
Why?
|
| Mental Health | 1 | 2024 | 3253 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 615 | 0.020 |
Why?
|
| Base Sequence | 1 | 2019 | 12420 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2011 | 244 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 645 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 6174 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2925 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2023 | 8473 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2018 | 64572 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 2164 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7805 | 0.020 |
Why?
|
| Time Factors | 2 | 2020 | 39908 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2017 | 2175 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2022 | 12942 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 1529 | 0.010 |
Why?
|
| Inpatients | 1 | 2016 | 2545 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2019 | 6561 | 0.010 |
Why?
|
| Cause of Death | 1 | 2013 | 3683 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10759 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4739 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168202 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39062 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16572 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14649 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 17630 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12934 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 3196 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2010 | 2688 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 12977 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 12043 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15829 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 169092 | 0.000 |
Why?
|